Krystal Biotech Inc’s recent filing unveils that its President, R&D Krishnan Suma unloaded Company’s shares for reported $2.02 million on Jul 14 ’25. In the deal valued at $150.30 per share,13,435 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,443,276 shares worth roughly $236.08 million.
Then, Krishnan Suma sold 13,400 shares, generating $2,014,015 in total proceeds. Upon selling the shares at $150.30, the President, R&D now owns 1,512,529 shares.
Before that, Krishnan Suma sold 3,084 shares. Krystal Biotech Inc shares valued at $465,700 were divested by the President, R&D at a price of $151.01 per share. As a result of the transaction, Krishnan Suma now holds 1,509,445 shares, worth roughly $246.9 million.
Jefferies initiated its Krystal Biotech Inc [KRYS] rating to a Buy in a research note published on March 05, 2025; the price target was $245. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Neutral”. Goldman began covering KRYS with “Buy” recommendation on November 20, 2023. Cantor Fitzgerald started covering the stock on October 24, 2023. It rated KRYS as “an Overweight”.
Price Performance Review of KRYS
On Friday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock jump 1.84% to $163.57. Over the last five days, the stock has gained 13.84%. Krystal Biotech Inc shares have fallen nearly -13.57% since the year began. Nevertheless, the stocks have risen 4.41% over the past one year.
How much short interest is there in Krystal Biotech Inc?
A steep rise in short interest was recorded in Krystal Biotech Inc stocks on 2025-08-29, growing by 49923.0 shares to a total of 3.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.4 million shares. There was a rise of 1.45%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 12, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $160 price target.
